These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33803006)

  • 1. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors.
    Castello A; Rossi S; Toschi L; Lopci E
    J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33803006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors.
    Castello A; Carbone FG; Rossi S; Monterisi S; Federico D; Toschi L; Lopci E
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32092983
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Polverari G; Ceci F; Bertaglia V; Reale ML; Rampado O; Gallio E; Passera R; Liberini V; Scapoli P; Arena V; Racca M; Veltri A; Novello S; Deandreis D
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32380754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
    Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
    Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive Value of Total Metabolic Tumor Burden Prior to Treatment in NSCLC Patients Treated with Immune Checkpoint Inhibition.
    Kudura K; Ritz N; Templeton AJ; Kutzker T; Foerster R; Antwi K; Kreissl MC; Hoffmann MHK
    J Clin Med; 2023 May; 12(11):. PubMed ID: 37297920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
    Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between antibiotics and adverse oncological outcomes in patients receiving targeted or immune-based therapy for hepatocellular carcinoma.
    Pinato DJ; Li X; Mishra-Kalyani P; D'Alessio A; Fulgenzi CAM; Scheiner B; Pinter M; Wei G; Schneider J; Rivera DR; Pazdur R; Theoret MR; Casak S; Lemery S; Fashoyin-Aje L; Cortellini A; Pelosof L
    JHEP Rep; 2023 Jun; 5(6):100747. PubMed ID: 37197442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    Castello A; Toschi L; Rossi S; Mazziotti E; Lopci E
    J Cancer Res Clin Oncol; 2020 May; 146(5):1235-1243. PubMed ID: 32048008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
    Iglesias-Santamaría A
    Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters.
    Castello A; Rossi S; Toschi L; Mansi L; Lopci E
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32471030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
    Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
    Ding CY; Guo Z; Li YY; Li TR
    Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
    [No Abstract]   [Full Text] [Related]  

  • 18. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of
    Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E
    J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes.
    Lang D; Ritzberger L; Rambousek V; Horner A; Wass R; Akbari K; Kaiser B; Kronbichler J; Lamprecht B; Gabriel M
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
    Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
    Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.